Big biotechs will do just fine in the ongoing financial crisis, but the smaller companies will have more difficulty weathering the storm.
Apr 1, 2009
By:G. Steven Burrill
Big biotechs will do just fine in the ongoing financial crisis, but the smaller companies will have more difficulty weathering the storm.
 |
Small biotechs were forced to restructure and downsize.
Jan 1, 2009
By:G. Steven Burrill
Small biotechs were forced to restructure and downsize.
|
The meltdown in the financial markets will continue to affect the flow of much needed capital into the sector.
Dec 1, 2008
By:G. Steven Burrill
The meltdown in the financial markets represents a sea change in the world of financing that will continue to affect the flow of much needed capital into the sector for the foreseeable future.
|
As the financial markets settle down, we will continue to see the biotech industry benefit from increase M&A activity.
Oct 1, 2008
By:G. Steven Burrill
The biotech industry's year-to-date report card contains good grades despite the turbulent economic climate.
|
In the current market crisis, biotech IPOs and financing are down, but partnering continues, and M&As are as hot as ever.
Jun 1, 2008
By:G. Steven Burrill
Following the market crisis of the first quarter of 2008, biotech IPOs and financing are down, but partnering continues, and mergers and acquisitions (M&As) remain hot.
|
Mar 1, 2008
By:G. Steven Burrill
Despite the rising fears about a slowing economy, the biotech industry will continue to maintain its momentum this year.
|
| 
